

---

**From:**  
**Sent:** 14 November 2013 17:17  
**To:** Appeals  
**Subject:** NICE Final Appraisal Determination for aflibercept

To whom it may concern

In July the National Institute for Health and Care Excellence (NICE) decided to reject the use of aflibercept in the treatment of colorectal cancer. As a charity representing and advocating for bowel cancer patients, we were disappointed with this decision even though NICE found aflibercept to be clinically effective in extending life in the later stages of advanced bowel cancer, and as having the potential to significantly impact on survival rates in future.

NICE states that it is “committed to involving patients, carers and the public in the development of its guidance”, yet we would raise concerns that there was limited patient, carer or public involvement in the development of this FAD. As the only patient group listed as a stakeholder for the appraisal, Beating Bowel Cancer wrote to NICE setting out our position on the FAD on 25 July. While we acknowledge that this was after the committee meeting of 23 July, we are disappointed that no effort was made to share our position among the committee. This is particularly surprising as a final decision on aflibercept was not received until 24 October – a full three months after the committee met.

We would like to appeal to the Final Appraisal Determination (FAD) for aflibercept on the basis that NICE failed to act fairly. We call on NICE to reconsider this decision in the light of our initial submission and would like this point to be considered as a written appeal.

Yours

Chief Executive

Email [@beatingbowelcancer.org](mailto:info@beatingbowelcancer.org)